A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Momelotinib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 18 Oct 2017 Tthe trial enrollment was halted, as dose limiting toxicities (DLTs) of grade 3 diarrhea and grade 4 neutropenia without fever were seen at dose level (DL) 2B, according to results presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Final results presented at the 18th World Conference on Lung Cancer.
    • 20 Mar 2017 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top